Mar 21, 2017 7:00 am EDT Heat Biologics Reports Positive Interim Phase 2 Lung Cancer Results in Patients Treated with HS-110 in Combination with a Checkpoint Inhibitor
Mar 20, 2017 7:00 am EDT Heat Biologics, Inc. to Present at The MicroCap Conference on April 4th in New York City
Mar 16, 2017 7:02 am EDT Florida Department of Health Awards Three-Year Grant to Develop gp96-based Zika Vaccine
Mar 13, 2017 7:00 am EDT Heat Biologics Meets Efficacy Endpoint in its Phase 1b Lung Cancer Trial to Progress to Phase 2